2026-01-23 - Analysis Report
**Company Overview**
Thermo Fisher Scientific is a global life sciences and laboratory equipment company.

**Return Rate Analysis**
* Cumulative return of review stock (TMO) = **46.10%**
* Cumulative return of comparison stock (VOO) = **92.53%**
* Divergence (max: 60.00, min: -70.50, current: -51.90, relative divergence: 14.30%)

The review stock (TMO) has a lower cumulative return compared to the comparison stock (VOO). The divergence is -51.90, with a relative divergence of 14.30%.

**Alpha, Beta Analysis**
* | Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
* |------------|------|------|-------|------|-------|
* | 2016-2018  | 21.0% | 17.1% | 16.0% | 1.1 | 84.1B |
* | 2017-2019  | 46.0% | 17.1% | 29.0% | 1.1 | 122.1B |
* | 2018-2020  | 22.0% | 17.1% | 1.0% | 0.8 | 175.0B |
* | 2019-2021  | 77.0% | 15.0% | 34.0% | 0.8 | 250.7B |
* | 2020-2022  | 8.0% | 25.4% | 10.0% | 0.8 | 206.9B |
* | 2021-2023  | -30.0% | 28.6% | -31.0% | 0.9 | 199.4B |
* | 2022-2024  | -37.0% | 24.4% | -57.0% | 0.9 | 195.4B |
* | 2023-2025  | -17.0% | 27.2% | -79.0% | 0.8 | 217.7B |

The review stock (TMO) has shown volatile returns over the years, with both positive and negative CAGR values. The Alpha and Beta values vary across different periods, indicating differing levels of performance.

**Stock Price Fluctuations**
* Close = **$639.45**
* Last-market = {'price': 639.45, 'previousClose': 636.3, 'change': 0.5}
* 5-day SMA = **$627.63**
* 20-day SMA = **$606.86**
* 60-day SMA = **$584.94**

The stock price is currently showing a slight increase, with a close of $639.45 and a 5-day SMA of $627.63. The 20-day SMA and 60-day SMA are lower, indicating a downtrend in the longer term.

**RSI, PPO Analysis**
* Market Risk Indicator (MRI) = **0.90** (0.9~1.0: High Investment Recommended, 0.7~0.9: Medium Investment, 0.4~0.7: Low Investment, <0.4: Very Risky)
* RSI = **74.22**
* PPO = **0.36**
* Hybrid Signal: Buy (Cash 0%)
Risk Level: High (MRI 0.90)
* Recent (20 days) relative divergence change = 0.60 (+): improving
* 7-day Rank change = 31 (+): rank up
* 7-day Dynamic Expected Return change = -2.90 (-): worsening
* Expected Return (%) = **-43.90%**, Expected excess return compared to S&P 500 if invested long-term (more than 2 years) from this point.

The stock has an RSI value of 74.22, indicating it may be overbought. The PPO value is 0.36, suggesting a potential reversal. The MRI is high, but the expected return is negative, indicating a high risk investment.

**Recent News & Significant Events**
* [2026-01-22] Thermo Fisher Scientific (TMO) reports next week: Wall Street expects earnings growth - MSN
* [2026-01-06] Will Thermo Fisher (TMO) Beat Estimates Again in Its Next Earnings Report? - Yahoo Finance
* [2026-01-06] Here's How Much You'd Have If You Invested $1000 in Thermo Fisher Scientific a Decade Ago - Nasdaq
* [2026-01-22] Thermo Fisher’s AI Lab Push And Leadership Shift Might Change The Case For Investing In TMO - simplywall.st
* [2026-01-22] 16,416 Shares in Thermo Fisher Scientific Inc. $TMO Acquired by Rakuten Investment Management Inc. - MarketBeat
* [2026-01-22] Thermo Fisher stock price today: TMO steadies near a 52-week high ahead of Jan. 29 earnings - TechStock²

Recent news and events suggest that the company is expected to release earnings soon, with analysts anticipating growth. However, the stock price has remained steady near a 52-week high.

**Analyst Opinions**
* Analyst Consensus:
- Key: Buy
- Mean (1=StrongBuy~5=Sell): **1.54 (~Buy)**
- Opinions: **23**
- Target Price (avg/high/low): **$652.61 / $750.00 / $575.00**

Analysts have a consensus of buy, with a mean rating of 1.54. The target price range is between $652.61 and $750.00.

**Recent Earnings Analysis**
* | Date | EPS | Revenue |
* |---|---:|---:|
* | 2025-10-31 | 4.28 | $11.12 B$ |
* | 2025-08-01 | 4.28 | $10.86 B$ |
* | 2025-05-02 | 3.99 | $10.36 B$ |
* | 2024-11-01 | 4.26 | $10.60 B$ |
* | 2025-10-31 | 4.26 | $10.60 B$ |

The company has reported EPS and revenue growth in recent quarters, with a slight decline in the latest quarter.

**Financial Information - Revenue and Profitability**
* | Quarter | Revenue | Profit Margin |
* |---------|----------|---------------|
* | 2025-09-30 | $11.12B | 41.21% |
* | 2025-06-30 | $10.85B | 40.61% |
* | 2025-03-31 | $10.36B | 40.86% |
* | 2024-12-31 | $11.39B | 42.32% |
* | 2024-09-30 | $10.60B | 40.84% |

Revenue and profit margins have shown fluctuations across different quarters, with a slight decline in the latest quarter.

**Financial Information - Capital and Profitability**
* | Quarter | Equity | ROE |
* |---------|---------|-----|
* | 2025-09-30 | $51.02B | 3.17% |
* | 2025-06-30 | $50.51B | 3.20% |
* | 2025-03-31 | $49.39B | 3.05% |
* | 2024-12-31 | $49.59B | 3.69% |
* | 2024-09-30 | $48.99B | 3.33% |

The company's equity has shown fluctuations, with a slight decline in the latest quarter. ROE has also shown fluctuations, with a decrease in the latest quarter.

**Comprehensive Analysis (Summary)**
The review stock (TMO) has shown volatile returns, with a lower cumulative return compared to the comparison stock (VOO). The stock price is currently showing a slight increase, but the 20-day SMA and 60-day SMA are lower, indicating a downtrend in the longer term. The MRI is high, but the expected return is negative, indicating a high risk investment. Recent news and events suggest that the company is expected to release earnings soon, with analysts anticipating growth. However, the stock price has remained steady near a 52-week high. The company's EPS and revenue growth have been consistent in recent quarters, but revenue and profit margins have shown fluctuations. The company's equity and ROE have also shown fluctuations in recent quarters, with a decrease in the latest quarter.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.